Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis
Abstract Background Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urge...
Saved in:
Main Authors: | Zihao Chen, Xin Chen, Dingchao Li, Jingang jian, Chang Yao, Xuedong Wei, Jianquan Hou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Urology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12894-024-01675-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01) -
Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies
by: Inmaculada Ruiz-Lorente, et al.
Published: (2025-01-01) -
Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain
by: Hideyuki Isobe, et al.
Published: (2025-01-01) -
A systematic review on the correlation between COVID-19 and lower urinary tract symptoms
by: Ashkan Shafigh, et al.
Published: (2025-02-01) -
Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024-11-01)